8 results on '"Strinich T"'
Search Results
2. The effect of C5 inhibition by eculizumab on allergen-induced asthmatic responses: 35
- Author
-
Gauvreau, G, Boulet, L, Severino, B, Watson, R, Peng, T, Obminski, G, Prince, P, Deschesnes, F, Strinich, T, Killian, K, Cote, J, Wang, Y, and OʼByrne, P
- Published
- 2009
3. Circulating myeloid and plasmacytoid dendritic cells after allergen inhalation in asthmatic subjects
- Author
-
Farrell, E., OʼConnor, T. M., Duong, M., Watson, R. M., Strinich, T., Gauvreau, G. M., and OʼByrne, P. M.
- Published
- 2007
4. Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects
- Author
-
Deschesnes Francine, Milot Joanne, Killian Kieran J, Duong MyLinh, Côté Johanne, Schmid-Wirlitsch Christine, Boulet Louis-Philippe, Gauvreau Gail M, Strinich Tara, Watson Richard M, Bredenbröker Dirk, and O'Byrne Paul M
- Subjects
Allergic asthma ,allergen challenge ,PDE4 inhibitor ,inflammation ,sputum ,neutrophils ,eosinophils ,Diseases of the respiratory system ,RC705-779 - Abstract
Abstract Background Phosphodiesterase 4 (PDE4) inhibitors increase intracellular cyclic adenosine monophosphate (cAMP), leading to regulation of inflammatory cell functions. Roflumilast is a potent and targeted PDE4 inhibitor. The objective of this study was to evaluate the effects of roflumilast on bronchoconstriction, airway hyperresponsiveness (AHR), and airway inflammation in mild asthmatic patients undergoing allergen inhalation challenge. Methods 25 subjects with mild allergic asthma were randomized to oral roflumilast 500 mcg or placebo, once daily for 14 days in a double-blind, placebo-controlled, crossover study. Allergen challenge was performed on Day 14, and FEV1 was measured until 7 h post challenge. Methacholine challenge was performed on Days 1 (pre-dose), 13 (24 h pre-allergen), and 15 (24 h post-allergen), and sputum induction was performed on Days 1, 13, 14 (7 h post-allergen), and 15. Results Roflumilast inhibited the allergen-induced late phase response compared to placebo; maximum % fall in FEV1 (p = 0.02) and the area under the curve (p = 0.01). Roflumilast had a more impressive effect inhibiting allergen-induced sputum eosinophils, neutrophils, and eosinophil cationic protein (ECP) at 7 h post-allergen (all p = 0.02), and sputum neutrophils (p = 0.04), ECP (p = 0.02), neutrophil elastase (p = 0.0001) and AHR (p = 0.004) at 24 h post-allergen. Conclusions This study demonstrates a protective effect of roflumilast on allergen-induced airway inflammation. The observed attenuation of sputum eosinophils and neutrophils demonstrates the anti-inflammatory properties of PDE4 inhibition and supports the roles of both cell types in the development of late phase bronchoconstriction and AHR. Trial Registration ClinicalTrials.gov: NCT01365533
- Published
- 2011
- Full Text
- View/download PDF
5. Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects.
- Author
-
Gauvreau GM, Boulet LP, Schmid-Wirlitsch C, Côté J, Duong M, Killian KJ, Milot J, Deschesnes F, Strinich T, Watson RM, Bredenbröker D, and O'Byrne PM
- Subjects
- Adolescent, Adult, Asthma drug therapy, Cross-Over Studies, Cyclopropanes therapeutic use, Double-Blind Method, Female, Forced Expiratory Volume drug effects, Forced Expiratory Volume immunology, Humans, Male, Middle Aged, Pneumonia drug therapy, Pulmonary Eosinophilia chemically induced, Pulmonary Eosinophilia immunology, Pulmonary Eosinophilia pathology, Young Adult, Allergens toxicity, Aminopyridines therapeutic use, Asthma immunology, Asthma pathology, Benzamides therapeutic use, Phosphodiesterase 4 Inhibitors therapeutic use, Pneumonia immunology, Pneumonia pathology
- Abstract
Background: Phosphodiesterase 4 (PDE4) inhibitors increase intracellular cyclic adenosine monophosphate (cAMP), leading to regulation of inflammatory cell functions. Roflumilast is a potent and targeted PDE4 inhibitor. The objective of this study was to evaluate the effects of roflumilast on bronchoconstriction, airway hyperresponsiveness (AHR), and airway inflammation in mild asthmatic patients undergoing allergen inhalation challenge., Methods: 25 subjects with mild allergic asthma were randomized to oral roflumilast 500 mcg or placebo, once daily for 14 days in a double-blind, placebo-controlled, crossover study. Allergen challenge was performed on Day 14, and FEV1 was measured until 7 h post challenge. Methacholine challenge was performed on Days 1 (pre-dose), 13 (24 h pre-allergen), and 15 (24 h post-allergen), and sputum induction was performed on Days 1, 13, 14 (7 h post-allergen), and 15., Results: Roflumilast inhibited the allergen-induced late phase response compared to placebo; maximum % fall in FEV1 (p = 0.02) and the area under the curve (p = 0.01). Roflumilast had a more impressive effect inhibiting allergen-induced sputum eosinophils, neutrophils, and eosinophil cationic protein (ECP) at 7 h post-allergen (all p = 0.02), and sputum neutrophils (p = 0.04), ECP (p = 0.02), neutrophil elastase (p = 0.0001) and AHR (p = 0.004) at 24 h post-allergen., Conclusions: This study demonstrates a protective effect of roflumilast on allergen-induced airway inflammation. The observed attenuation of sputum eosinophils and neutrophils demonstrates the anti-inflammatory properties of PDE4 inhibition and supports the roles of both cell types in the development of late phase bronchoconstriction and AHR., Trial Registration: ClinicalTrials.gov: NCT01365533.
- Published
- 2011
- Full Text
- View/download PDF
6. Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses.
- Author
-
Gauvreau GM, Boulet LP, Cockcroft DW, Baatjes A, Cote J, Deschesnes F, Davis B, Strinich T, Howie K, Duong M, Watson RM, Renzi PM, and O'Byrne PM
- Subjects
- Administration, Inhalation, Adult, Asthma genetics, Asthma metabolism, Cross-Over Studies, Double-Blind Method, Drug Combinations, Female, Flow Cytometry, Follow-Up Studies, Forced Expiratory Volume, Gene Expression, Humans, Male, Middle Aged, Nebulizers and Vaporizers, Oligonucleotides, Antisense administration & dosage, Phosphorothioate Oligonucleotides administration & dosage, Pulmonary Eosinophilia genetics, Pulmonary Eosinophilia metabolism, RNA, Messenger genetics, Receptors, CCR3 genetics, Receptors, CCR3 metabolism, Receptors, Cytokine genetics, Reverse Transcriptase Polymerase Chain Reaction, Sputum cytology, Sputum metabolism, Treatment Outcome, Allergens adverse effects, Asthma drug therapy, Oligonucleotides, Antisense therapeutic use, Phosphorothioate Oligonucleotides therapeutic use, Pulmonary Eosinophilia drug therapy, Receptors, CCR3 antagonists & inhibitors, Receptors, Cytokine metabolism
- Abstract
Rationale: The drug product TPI ASM8 contains two modified phosphorothioate antisense oligonucleotides designed to inhibit allergic inflammation by down-regulating human CCR3 and the common beta chain (beta(c)) of IL-3, IL-5, and granulocyte-macrophage colony-stimulating factor receptors., Objectives: This study examined the effects of inhaled TPI ASM8 on sputum cellular influx, CCR3 and beta(c) mRNA and protein levels, and the airway physiologic response after inhaled allergen., Methods: Seventeen subjects with mild atopic asthma were randomized in a crossover study to inhale 1,500 microg TPI ASM8 or placebo by nebulizer, once daily for 4 days. On Day 3, subjects underwent allergen inhalation challenge. Sputum samples were collected before and after allergen. CCR3 and beta(c) protein levels were measured by flow cytometry, mRNA was measured using real-time quantitative polymerase chain reaction, and the FEV1 was measured over 7 hours after challenge., Measurements and Main Results: Compared with placebo, TPI ASM8 inhibited sputum eosinophil influx by 46% (P = 0.02) and blunted the increase in total cells (63%) after allergen challenge. TPI ASM8 significantly reduced the early asthmatic response (P = 0.04) with a trend for the late asthmatic response (P = 0.08). The allergen-induced (Day 2 to Day 3) levels of beta(c) mRNA and CCR3 mRNA in sputum-derived cells were inhibited by TPI ASM8 (P = 0.039 and P = 0.054, respectively), with no significant effects on the cell surface protein expression of CCR3 and beta(c) (P > 0.05). No serious adverse events were reported., Conclusions: TPI ASM8 attenuates the allergen-induced increase in target gene mRNA and airway responses in subjects with mild asthma. Clinical trial registered with www.clinicaltrials.gov (NCT 00264966).
- Published
- 2008
- Full Text
- View/download PDF
7. Sputum eosinophils and the response of exercise-induced bronchoconstriction to corticosteroid in asthma.
- Author
-
Duong M, Subbarao P, Adelroth E, Obminski G, Strinich T, Inman M, Pedersen S, and O'Byrne PM
- Subjects
- Adolescent, Adult, Anti-Allergic Agents administration & dosage, Anti-Allergic Agents therapeutic use, Cross-Over Studies, Double-Blind Method, Female, Forced Expiratory Volume, Humans, Leukocyte Count, Male, Pregnenediones administration & dosage, Pregnenediones therapeutic use, Spirometry, Anti-Allergic Agents pharmacology, Asthma drug therapy, Asthma physiopathology, Bronchoconstriction drug effects, Eosinophils physiology, Pregnenediones pharmacology, Sputum chemistry
- Abstract
Background: The relationship between eosinophilic airway inflammation and exercise-induced bronchoconstriction (EIB), and the response to inhaled corticosteroid (ICS) therapy was examined., Methods: Twenty-six steroid-naïve asthmatic patients with EIB were randomized to two parallel, double-blind, crossover study arms (13 subjects in each arm). Each arm compared two dose levels of inhaled ciclesonide that were administered for 3 weeks with a washout period of 3 to 8 weeks, as follows: (1) 40 vs 160 microg daily; and (2) 80 vs 320 microg daily. Baseline and weekly assessments with exercise challenge and sputum analysis were performed., Results: Data were pooled and demonstrated that 10 subjects had baseline sputum eosinophilia >or= 5%. Only high-dose ICS therapy (ie, 160 and 320 microg) significantly attenuated the sputum eosinophil percentage. Sputum eosinophil percentage significantly correlated with EIB severity, and predicted the magnitude and temporal response of EIB to high-dose therapy, but not to low-dose therapy (ie, 40 and 80 microg). Low-dose ICS therapy provided a significant reduction in EIB at 1 week, with little additional improvement thereafter, irrespective of baseline sputum eosinophil counts. In contrast, high-dose ICS therapy provided a significantly greater improvement in EIB in subjects with sputum eosinophilia compared to those with an eosinophil count of < 5%. The difference between the eosinophilic groups in the magnitude of improvement in EIB was evident after the first week of high-dose ICS therapy and increased with time., Conclusions: These results suggest that eosinophilic airway inflammation may be important in modifying the severity of EIB and the response to ICS therapy. Measurements of sputum eosinophil percentage may, therefore, be useful in predicting the magnitude and temporal response of EIB to different dose levels of ICSs., Trial Registration: clinicaltrial.gov; Identifier: NCT00525772.
- Published
- 2008
- Full Text
- View/download PDF
8. The effects of inhaled budesonide and formoterol in combination and alone when given directly after allergen challenge.
- Author
-
Duong M, Gauvreau G, Watson R, Obminski G, Strinich T, Evans M, Howie K, Killian K, and O'Byrne PM
- Subjects
- Administration, Inhalation, Adolescent, Adult, Bronchial Hyperreactivity drug therapy, Cross-Over Studies, Double-Blind Method, Drug Therapy, Combination, Female, Forced Expiratory Volume drug effects, Formoterol Fumarate, Humans, Male, Methacholine Chloride pharmacology, Allergens immunology, Asthma drug therapy, Budesonide administration & dosage, Ethanolamines administration & dosage
- Abstract
Background: The use of combination inhaled budesonide and formoterol as maintenance and reliever therapy significantly improves the risk and the time to exacerbations in asthma., Objectives: To explore the mechanisms underlying the effect of the reliever dose on exacerbations by examining the effect of combination therapy on the allergen challenge model when given after allergen exposure., Methods: In a randomized, double-blind crossover study, single doses of budesonide/formoterol (400/12 mug), formoterol (12 mug), budesonide (400 mug), or placebo were administered during the acute bronchoconstriction response (early airway response) immediately after allergen inhalation in 15 patients with mild asthma. Allergen-induced late airway response (LAR), sputum inflammatory markers, airway hyperresponsiveness, and exhaled nitric oxide were measured., Results: All active treatments significantly attenuated the LAR, with budesonide/formoterol significantly better than its monocomponents (maximum FEV(1) fall: placebo, [mean +/- SEM] 21.2% +/- 3.1%; budesonide/formoterol, 4.2% +/- 1.4%; formoterol, 7.5% +/- 1.7%; budesonide, 10.4% +/- 1.6%). Allergen-induced change in methacholine PC(20) was significantly attenuated by budesonide/formoterol, but not by its monocomponents. Sputum cell counts and exhaled nitric oxide increased significantly after all allergen challenges, with no significant attenuation by any of the treatments. Therapy with combination and formoterol alone, but not budesonide, significantly reduced the early airway response., Conclusion: A single dose of budesonide/formoterol was superior to its monocomponents in attenuating the allergen-induced LAR and airway hyperresponsiveness. These effects may represent the contribution of the reliever dose to the budesonide/formoterol maintenance and reliever regimen., Clinical Implications: The protective effect against allergic airway responses with a single reliever dose of budesonide/formoterol is predominantly related to greater functional antagonism of airway smooth muscles.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.